{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04140539: Phase 2/Phase 3 Interventional Withdrawn Severe Combined Immunodeficiency Due to ADA Deficiency
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03493945: Phase 1/Phase 2 Interventional Completed Metastatic Prostate Cancer
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03562494: Phase 1 Interventional Completed Parkinson's Disease
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02063789: Phase 3 Interventional Completed Immune Thrombocytopenia
(2014)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03420963: Phase 1 Interventional Recruiting Recurrent Cutaneous Melanoma
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01145560: Phase 2 Interventional Completed Severe Sepsis
(2010)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:surabgene lomparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04431934: Not Applicable Interventional Unknown status CARRIER STATE
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04431934: Not Applicable Interventional Unknown status CARRIER STATE
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04428476: Phase 2 Interventional Active, not recruiting Duchenne Muscular Dystrophy
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE